A/Prof Joe Cardaci

Nuclear Medicine Physician

A/Prof Joe Cardaci

MBBS FAANMS FRACP

Contact
Joe graduated from the University of Western Australia and subsequently completed his specialty training in nuclear medicine with the Royal Australasian College of Physicians through Royal Perth Hospital and Sir Charles Gairdner Hospital. He entered private practice at an early stage of his career and was a visiting specialist at Royal Perth Hospital. Joe’s interest in nuclear medicine is predominantly in therapeutic applications. He was involved in the early clincial trials of SIR-Spheres in the treatment of liver tumours, and continues an active clinical service in the multidisciplinary treatment of these tumours.  His therapy interests also include the use of alpha and beta particle therapy for bone tumours, and radioiodine therapy of thyroid diseases. In conjunction with Theranostics Australia and, subsequently, GenesisCare, Joe established the first private lutetium radiopeptide therapy service in Australia, treating mainly advanced prostate and neuroendocrine tumours. He has participated in clinical trials using radionuclide therapies in prostate, colorectal and neuroendocrine tumours. In addition to his nuclear medicine duties, Joe actively practices as a general medicine physician at Hollywood Private Hospital. He is involved in undergraduate and postgraduate medical education, and is Adjunct Associate Professor at the University of Notre Dame.

A/Prof Nat Lenzo

Nuclear Medicine Physician

A/Prof Nat Lenzo

BSc BMedSci(Hons) MBBS MMed MHSvMgt EMBA FRACP FAANMS GAICD

Contact
Nat graduated in medicine from the University of Western Australia and then completed a fellowship in nuclear medicine at the University of Michigan. Apart from undergraduate science, research and medical degrees, he also holds master’s degrees in medicine, health service management and business administration, and is currently completing a masters in advanced oncology at Ulm University in Germany. From 2001 – 2006, Nat was the inaugural head of the Western Australian PET/cyclotron service based at Sir Charles Gairdner Hospital. Previously, he also held head of department positions at Royal Perth Hospital and Fremantle Hospital. Currently, Nat is an associate clinical professor at the University of Western Australia, fellow of health sciences at Macquarie University Hospital in Sydney, consultant nuclear physician at Fiona Stanley Hospital, and general physician at St John of God Hospital Murdoch. With a strong track record in developing clinical and research services in the public and private sectors, Nat’s research interests are in new molecular imaging and targeted therapeutic agents in neurosciences and oncology. He is the co-investigator on a number of grants, a principal investigator in several multicentre clinical trials, and a co-author on 50 peer reviewed publications, predominantly in the areas of molecular imaging and therapy in neuroscience and oncology. In 2015, Nat founded Theranostics Australia, now fully owned by GenesisCare, where he remains in the position of clinical director. He is committed to expanding the field of theranostics with GenesisCare in Australia and overseas.

Whether it’s for diagnosis or treatment, patients attending the PCC are treated as individuals by a team of specialist doctors and allied health professionals with complimentary skill sets who really do care. It’s a true multidisciplinary approach.

It’s what makes the PCC different.